Longboard Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Employees: 50

Market Cap: $1.3B

Website: http://www.longboardpharma.com

Introduction: Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for neurological diseases. The company was founded on January 3, 2020 and is headquartered in San Diego, CA.

Clinical Trials

A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)

Phase 3

Recruiting

Conditions: Developmental and Epileptic Encephalopathy

Interventions: Drug: LP352
Drug: Placebo

First Posted Date: 2024-12-05

Last Posted Date: 2024-12-05

Lead Sponsor: Longboard Pharmaceuticals

Target Recruit Count: 320

Registration Number: NCT06719141

Locations: 🇺🇸
Site Number - USA02, Gulf Breeze, Florida, United States
🇺🇸
Site Number - USA05, Orlando, Florida, United States
🇺🇸
Site Number - USA11, Tampa, Florida, United States

and more 4 locations

A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults with Dravet Syndrome (DS)

Phase 3

Recruiting

Conditions: Dravet Syndrome

Interventions: Drug: LP352
Drug: Placebo

First Posted Date: 2024-10-28

Last Posted Date: 2024-10-28

Lead Sponsor: Longboard Pharmaceuticals

Target Recruit Count: 160

Registration Number: NCT06660394

Locations: 🇺🇸
Site Number - USA02, Gulf Breeze, Florida, United States
🇺🇸
Site Number - USA05, Orlando, Florida, United States
🇺🇸
Site Number - USA11, Tampa, Florida, United States

and more 4 locations

Intermediate-Size Expanded Access Protocol (EAP) for LP352

Conditions: Dravet Syndrome
Lennox Gastaut Syndrome
Developmental and Epileptic Encephalopathies

First Posted Date: 2023-11-29

Last Posted Date: 2024-02-28

Lead Sponsor: Longboard Pharmaceuticals

Registration Number: NCT06149663

Locations: 🇺🇸
Mid-Atlantic Epilepsy and Sleep Center, Bethesda, Maryland, United States
🇺🇸
Northwest Florida Clinical Research Group, Gulf Breeze, Florida, United States
🇺🇸
Research Institute of Orlando, Orlando, Florida, United States

Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy

Phase 2

Active, not recruiting

Conditions: Lennox-Gastaut Syndrome
Dravet Syndrome
Developmental and Epileptic Encephalopathy

Interventions: Drug: LP352, bexicaserin

First Posted Date: 2022-11-25

Last Posted Date: 2024-12-04

Lead Sponsor: Longboard Pharmaceuticals

Target Recruit Count: 50

Registration Number: NCT05626634

Locations: 🇺🇸
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸
Northeast Regional Epilepsy Group, Staten Island, New York, United States
🇺🇸
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States

and more 25 locations

Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies

Phase 1

Completed

Conditions: Developmental and Epileptic Encephalopathy
Lennox Gastaut Syndrome
Dravet Syndrome

Interventions: Drug: Placebo
Drug: LP352

First Posted Date: 2022-05-06

Last Posted Date: 2024-11-08

Lead Sponsor: Longboard Pharmaceuticals

Target Recruit Count: 52

Registration Number: NCT05364021

Locations: 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸
Consultants in Epilepsy and Neurology, Boise, Idaho, United States
🇦🇺
Royal Brisbane Women's Hospital, Herston, Queensland, Australia

and more 31 locations

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy